| 期 |
栏目 |
标题 |
文件 |
| 编号 9 (2017) |
Articles |
ALGORITHM OF THE SELECTION OF ANTIHYPERTENSIVE THERAPY AGAINST THE INVOLVEMENT OF HEART AS A TARGET ORGAN IN ARTERIAL HYPERTENSION |
|
| 编号 15 (2017) |
Articles |
Possibilities of amlodipine/lisinopril fixed-dose combination in real clinical practice |
|
| 卷 26, 编号 9 (2019) |
Articles |
Drug-induced nightmares |
|
| 卷 26, 编号 14 (2019) |
Articles |
Drug-induced hyperthyroidism |
|
| 卷 27, 编号 2 (2020) |
Articles |
Medicines associated with the development of drug-induced constipation |
|
| 卷 27, 编号 4 (2020) |
Articles |
Individual drugs associated with overweight inducing |
|
| 卷 27, 编号 3 (2020) |
Articles |
Approaches to choosing a direct oral anticoagulant in the treatment of polymorbid patients with atrial fibrillation |
|
| 卷 27, 编号 3 (2020) |
Articles |
Drug-induced hypothyroidism |
|
| 卷 27, 编号 5 (2020) |
Articles |
Drug-induced diseases: epidemiology and urgency of the problem |
|
| 卷 27, 编号 6 (2020) |
Articles |
Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance |
|
| 卷 27, 编号 13 (2020) |
Articles |
The role of the disturbances in the intestinal barrier structure in relation to cardiovascular diseases pathogenesis and rebamipid potential in their correction |
|
| 卷 28, 编号 2 (2021) |
Articles |
Drug-induced autoimmune hepatitis |
|
| 卷 28, 编号 3 (2021) |
Articles |
The relationship of cardiovascular disease with increased intestinal permeability: results from scientific and controlled clinical trials. Focus on the potential of rebamipide |
|
| 卷 28, 编号 3 (2021) |
Articles |
The choice of antianginal therapy for polymordib patients with coronary artery disease and type 2 diabetes mellitus: the benefits of trimetazidine |
|
| 卷 28, 编号 5 (2021) |
Articles |
Tobacco smoking as a risk factor for the development of drug-induced diseases |
|
| 卷 28, 编号 11 (2021) |
Articles |
Risk factors of drug-induced diseases. Part 1. Classification, non-modified risk factors |
|
| 卷 28, 编号 11 (2021) |
Articles |
Medication errors as risk factor for drug-induced diseases |
|
| 卷 28, 编号 12 (2021) |
Articles |
Risk factors of drug-induced diseases. Part 2. Comorbid diseases and lifestyle factors |
|
| 卷 29, 编号 1 (2022) |
Articles |
Risk factors of drug-induced diseases. Part 3. Drug-drug and drug-food interactions |
|
| 卷 29, 编号 3 (2022) |
Articles |
Risk factors of drug-induced diseases. Part 4. Medication errors and patient adherence |
|
| 卷 29, 编号 13 (2022) |
Articles |
Controversial and unresolved aspects of drug-induced hemorrhagic stroke: focus on selective serotonin reuptake inhibitors, non-steroidal anti-inflammatory drugs and statins |
|
| 卷 29, 编号 13 (2022) |
Articles |
Structure of prescription of gastroprotective drugs in patients receiving direct oral anticoagulants: results of a multicenter cross-sectional pharmacoepidemiological study |
|
